Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation

Han Hsi Wong; Christine Parkinson; Jonathan A Ledermann; James D Brenton; Michael Merger; Ashley Shaw; Aileen Patterson; Mahmood Shafi; Helena M Earl

doi:10.1016/j.gynor.2012.10.003

Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation

Gynecol Oncol Case Rep. 2012 Oct 17:3:7-10. doi: 10.1016/j.gynor.2012.10.003. eCollection 2012.

Authors

Han Hsi Wong¹, Christine Parkinson¹, Jonathan A Ledermann², James D Brenton³, Michael Merger⁴, Ashley Shaw¹, Aileen Patterson¹, Mahmood Shafi¹, Helena M Earl⁵

Affiliations

¹ Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, UK.
² Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, 90 Tottenham Court Road, London W1T 4TJ, UK.
³ Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
⁴ Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
⁵ Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Hills Road, Cambridge CB2 0QQ, UK.

Abstract

► Nintedanib is an anti-angiogenic agent that has demonstrated activity in relapsed ovarian cancer. ► Our patient had prolonged response to nintedanib, allowing her to have potentially curative surgery 6 years after her diagnosis. ► The relationship between angiogenesis and BRCA mutation is worth exploring in ovarian cancer.

Keywords: Angiogenesis; BIBF 1120; BRCA; Nintedanib; Ovarian cancer; VEGF.

Grants and funding

G0701383/MRC_/Medical Research Council/United Kingdom